As anti-PD1 efficacy can be limited by itIC abundance44, particularly of CD4+ T and memory CD4+ T cells10,45–49, we tested whether the ability to increase CD4+ T cell-mediated itIC induction and tumor suppression using oral l-fuc could be leveraged to augment anti-PD1 efficacy. Here, CD4 is linked to neoplasm.